Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News MSD sees Merck KGaA generics businesses sold

MSD sees Merck KGaA generics businesses sold

4th June 2008

Pharmaceutical company Mylan has entered into an acquisition agreement to buy the central and eastern European generics businesses of Merck KGaA, it has been revealed.

Following a previous agreement, this includes Merck’s operations in Slovakia, Slovenia, Hungary, Poland and the Czech Republic.

Mylan had already exercised an option to purchase the company’s generics businesses in the west of the continent, North America, Asia-Pacific and Africa.

Merck KGaA was also in the news this week following new analyses of randomised, controlled trials of Erbitux (cetuximab) as a treatment for first-line metastatic colorectal cancer.

Results from the phase III Crystal and phase II Opus studies found patients with a certain type of tumour who received Erbitux alongside chemotherapy displayed enhanced efficacy compared to those with a different tumour mutation.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.